Persson Kristina E M, Lee Chee T, Marsh Kevin, Beeson James G
The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia.
J Clin Microbiol. 2006 May;44(5):1665-73. doi: 10.1128/JCM.44.5.1665-1673.2006.
Antibodies that inhibit replication of Plasmodium falciparum in erythrocytes are thought to be important both in acquired immunity to malaria and as mediators of immunity generated by candidate blood-stage vaccines. However, several constraints have limited the study of these functional antibodies in population studies and vaccine trials. We report the development and optimization of high-throughput growth inhibition assays with improved sensitivity that use minimal volumes of test serum. The major inhibitory activity of serum from exposed donors was antibody mediated, but nonspecific inhibitory factors were found in untreated serum. Culture volumes could be effectively reduced to 25 microl to limit amounts of test serum or inhibitors used in assays. Performing inhibition assays over two cycles of parasite replication gave greater sensitivity than single-cycle assays, and a simple two-cycle inhibition assay was developed that yielded highly reproducible results. Determination of parasite growth by flow cytometry was most suitable for high-throughput assays using small culture volumes and was more sensitive than parasite lactate dehydrogenase assays and less prone to error and variation than microscopy. We evaluated and optimized methods to remove antimalarials and nonspecific inhibitory factors from serum that are suitable for use with small volumes of samples that are typically obtained from clinical studies. Both microdialysis and immunoglobulin purification by ammonium sulfate precipitation were effective and practical. These methods should facilitate evaluation of vaccine trials and clinical studies of immunity and are also suitable for testing drugs and other compounds for antimalarial activity.
抑制恶性疟原虫在红细胞内复制的抗体,被认为在疟疾的获得性免疫以及作为候选血液期疫苗所产生免疫的介质方面都很重要。然而,一些限制因素制约了这些功能性抗体在人群研究和疫苗试验中的研究。我们报告了一种高通量生长抑制试验的开发与优化,该试验具有更高的灵敏度,且使用的试验血清量极少。暴露供体血清的主要抑制活性是由抗体介导的,但在未处理的血清中发现了非特异性抑制因子。培养体积可有效减少至25微升,以限制试验中所用血清或抑制剂的量。在两个寄生虫复制周期上进行抑制试验比单周期试验具有更高的灵敏度,并且开发了一种简单的双周期抑制试验,其结果具有高度的可重复性。通过流式细胞术测定寄生虫生长最适合使用小培养体积的高通量试验,并且比寄生虫乳酸脱氢酶试验更灵敏,比显微镜检查更不易出错和产生变异。我们评估并优化了从血清中去除抗疟药和非特异性抑制因子的方法,这些方法适用于处理通常从临床研究中获得的少量样本。微透析和硫酸铵沉淀法免疫球蛋白纯化都是有效且实用的。这些方法应有助于评估疫苗试验和免疫的临床研究,也适用于测试药物和其他化合物的抗疟活性。